News

September 21, 2017September 21, 2017

Opdivo, HPV Cancer Vaccine Combo Improves Response Rates in Oropharyngeal Cancer Patients

News

A Phase 2 clinical trial found that the combination of Opdivo (nivolumab) and a cancer vaccine increased response rates in patients with throat tumors (oropharyngeal tumors) caused by the human ... Read more

September 20, 2017

Tafinlar-Mekinist Combo is Highly Effective Adjuvant Therapy for Melanoma, Researchers Say

News

A combination of Tafinlar (dabrafenib) and Mekinist (trametinib) nearly halved the risk of relapse or death among patients with advanced melanoma with high-risk mutations, according to trial results presented at ... Read more

September 19, 2017September 19, 2017

Keytruda Better than Standard Treatment for Advanced Head and Neck Cancer, Keynote-040 Study Shows

News

Keytruda (pembrolizumab) may be more beneficial than standard therapy for patients whose head and neck cancer has spread or returned after a first round of chemotherapy. That’s the conclusion of a Phase 3 ... Read more

September 18, 2017

X4P-001 and Inlyta Combo Shows Promise Against Kidney Cancer, Trial Indicates

News

A combination of X4P-001 and Inlyta (axitinib) has shown signs of activity against clear cell renal cell carcinoma (ccRCC) in a Phase 1/2 clinical trial. X4 Pharmaceuticals, which developed X4P-001, presented the findings in a poster session at the ... Read more

September 15, 2017September 15, 2017

Imfinzi Reduces Risk of Disease Progression in Advanced NSCLC Patients, PACIFIC Trial Shows

News

Imfinzi (durvalumab) increased the time to disease progression or death in patients with advanced, non-small cell lung cancer (NSCLC) who had not progressed following standard care with platinum-based concurrent chemoradiotherapy, ... Read more

September 15, 2017September 15, 2017

Updated Phase 3 Trial Results Continue to Favor Keytruda as Second-Line Treatment for Bladder Cancer

News

Patients with advanced urothelial cancer who received one prior line of chemotherapy live significantly longer when given Keytruda (pembrolizumab) as a second-line treatment instead of the standard of care chemotherapy, ... Read more

September 14, 2017September 14, 2017

Rocapuldencel-T Improves Survival in Renal Cell Carcinoma Patients, Phase 3 Trial Suggests

News

Adding Rocapuldencel-T (AGS-003) to standard-of-care treatment may lengthen the survival of patients with newly diagnosed metastatic renal cell carcinoma, according to data presented at the European Society for Medical Oncology (ESMO) 2017 ... Read more

September 14, 2017

Immuno-oncology Becoming Established as Fifth Pillar of Cancer Therapy, Analysts Say

News

The analytics firm Global Data argues that immuno-oncology appears set to become a fifth pillar among the mainstay of cancer treatments made up of surgery, radiotherapy, chemotherapy, and other targeted ... Read more

September 13, 2017

Experts Discuss Role of Cancer Immunotherapy at Bristol-Myers Presentation, Panel Discussion

News

In just three years, Bristol-Myers Squibb (BMS) received more than 10 approvals for Opdivo (nivolumab), authored 12 publications in the New England Journal of Medicine, and was granted seven Breakthrough Therapy designations by the ... Read more

September 13, 2017September 13, 2017

Opdivo and Yervoy Combo Boosts Mesothelioma Survival, Phase 2 Clinical Trial Shows

News

More than half of the mesothelioma patients who received a combination of Bristol-Myers Squibb‘s checkpoint blockers Opdivo (nivolumab) and Yervoy (ipilimumab) lived a year or more after treatment, according to the ... Read more